Kansas City Star
Spark gene therapy improves vision, at least in short term: FDA
(Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration.
Correction: Genetic Frontiers-Blindness-Gene Therapy story
The FDA is Considering a Landmark Approval of Gene Therapy To Cure Blindness
Seeing hope: FDA panel considers gene therapy for blindness
View original article